Hydroxychloroquine remains a foundational therapy for rheumatologic conditions like systemic lupus erythematosus and rheumatoid arthritis. However, emerging evidence highlights the critical importance of recognising hydroxychloroquine cardiotoxicity in routine clinical practice. Although clinicians widely appreciate the immunomodulatory efficacy and favorable metabolic profile of the drug, cardiac adverse reactions often remain underdiagnosed. Consequently, understanding the dual spectrum of electrophysiological disturbances and structural myocardial damage is essential for physicians managing chronic therapy. Recent translational and clinical investigations provide valuable clarity on how this familiar therapeutic agent affects cardiac conduction and cellular integrity over time.

Clinical Spectrum of Hydroxychloroquine Cardiotoxicity

The clinical manifestations of cardiac toxicity linked to antimalarial therapies range from subtle electrocardiographic changes to severe cardiomyopathy. In a recent retrospective cohort analysis of 261 patients receiving long-term therapy, approximately 1.1% developed clinically significant adverse events that required immediate drug discontinuation. These severe presentations included newly diagnosed heart failure and advanced conduction abnormalities. Furthermore, an additional subset of patients required cessation due to emerging electrocardiographic alterations. Because early symptoms frequently mimic underlying autoimmune disease activity, clinicians often overlook initial myocardial involvement. Therefore, maintaining high diagnostic vigilance is paramount when patients report fatigue, unexplained dyspnea, presyncope, or palpitations during regular treatment reviews.

Electrophysiological Alterations and Conduction Delays

Electrocardiographic monitoring reveals that antimalarial exposure systematically alters cardiac repolarisation and atrioventricular conduction. Cohort data demonstrate that the median corrected QT interval increases significantly from a baseline of 413 ms to 421 ms during treatment. Similarly, the PR interval exhibits a modest yet statistically significant lengthening from 148 ms to 150 ms. Although these incremental changes appear minor across broad cohorts, they represent a measurable shift in electrical stability. Moreover, patients with concurrent electrolyte imbalances, pre-existing structural heart disease, or co-administered QT-prolonging drugs face an augmented risk of life-threatening ventricular arrhythmias, including torsades de pointes. Thus, regular baseline and follow-up electrocardiograms serve as indispensable tools to prevent serious arrhythmic events.

Ultrastructural and Cellular Pathophysiology

Translational research utilizing human-induced pluripotent stem cell-derived cardiomyocytes provides compelling evidence regarding intracellular toxicity. Exposure to therapeutic concentrations directly prolongs the corrected field potential duration and triggers spontaneous arrhythmic activity in cellular models. In addition, motion analyses confirm reduced peak relaxation velocity, signifying impaired diastolic relaxation dynamics. On an ultrastructural level, the medication disrupts lysosomal function and inhibits autophagic flux within myocardial cells. This autophagic blockade leads to cytoplasmic vacuolation and the accumulation of curvilinear bodies and myelinoid structures. Consequently, endomyocardial biopsy specimens frequently exhibit distinct lysosomal inclusion patterns that differentiate drug-induced toxicity from primary inflammatory myocarditis.

Differentiating Drug Toxicity from Autoimmune Myocarditis

Distinguishing drug-associated myocardial damage from lupus myocarditis or rheumatoid heart involvement presents a complex clinical challenge. Systemic autoimmune diseases naturally cause subclinical inflammation, pericarditis, and microvascular dysfunction. However, drug toxicity typically presents with concentric ventricular hypertrophy, preserved or mildly depressed ejection fraction with prominent diastolic impairment, and progressive conduction system blockades. Furthermore, cardiac magnetic resonance imaging and advanced echocardiography can help delineate diffuse myocardial fibrosis and strain abnormalities. When non-invasive imaging remains ambiguous, transmission electron microscopy via myocardial biopsy definitively identifies pathognomonic lysosomal storage bodies. Consequently, accurate histopathological differentiation prevents the inappropriate escalation of immunosuppression when drug withdrawal is actually indicated.

Surveillance and Risk Mitigation Strategies

Mitigating the hazards of chronic therapy requires a proactive, structured surveillance strategy. Clinicians should calculate cumulative lifetime doses, as total exposure directly correlates with increased cardiotoxicity risk. In addition, healthcare providers must routinely screen for modifiable risk factors, including renal impairment, hypokalemia, and hypomagnesemia. Periodic electrocardiographic tracking is strongly advised, especially after starting therapy or adding other medications that lengthen the repolarisation phase. Furthermore, when patients present with unexplained cardiac symptoms or new bundle branch blocks, prompt echocardiographic assessment and cardiologist consultation are imperative. Discontinuing the agent upon early detection of toxicity often halts structural deterioration and promotes gradual functional recovery.

Frequently Asked Questions

What are the earliest signs of cardiac toxicity from this medication?

The earliest indicators include progressive prolongation of the PR or QTc intervals on surface electrocardiography. Patients may initially remain entirely asymptomatic or report subtle non-specific complaints such as mild exercise intolerance, dizziness, and intermittent palpitations. Early surveillance detects these subclinical electrophysiological deviations before overt heart failure or advanced atrioventricular block develops.

How does the drug cause cellular damage in myocardial tissue?

The drug accumulates inside acidic lysosomes, raising intracellular pH and impairing essential lysosomal enzymatic degradation. This disruption halts normal autophagic clearance within cardiomyocytes, leading to the accumulation of glycogen and complex lipids. Over time, these aggregates form distinctive curvilinear inclusion bodies, impair contractile relaxation, and induce cellular apoptosis.

Is cardiac damage reversible after stopping the medication?

Complete or partial reversibility depends substantially on the timeliness of detection and drug cessation. If clinicians identify electrical conduction abnormalities or early diastolic dysfunction promptly, withdrawing the medication often stabilizes cardiac function. However, advanced cardiomyopathy with extensive myocardial replacement fibrosis may persist or progress despite immediate treatment cessation.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Shiba M et al. Clinical and Experimental Insights into Hydroxychloroquine-Associated Electrical Abnormalities and Cardiomyopathy. Eur Heart J Cardiovasc Pharmacother. 2026 Aug 25. doi: undefined. PMID: 42637670.

Chatre C et al. Cardiovascular toxicities associated with hydroxychloroquine and chloroquine: a systematic review. Circulation. 2018;138(16):1740-1742.

Nguyen LS et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation. 2020;142(3):303-305.

Harmon DM et al. Hydroxychloroquine-induced cardiomyopathy: a comprehensive review of clinical features, imaging, and management. Curr Heart Fail Rep. 2022;19(6):458-466.